AUBURN HILLS, Michigan, April 25 /PRNewswire/ --

RGIS announced today the Acquisition of PDSRS, a leading company in retail space planning software. PDSRS based in the UK is the developer of StorPlanner, a state of the art store optimization software application. StorPlanner, combined with RGIS's R-Map and Visual Retail applications, will provide a unique tool for every retailer to optimize the use of their store-space. With the addition of the PDSRS tools RGIS is now in a position to offer an unparalleled turn-key solution for store mapping services and an interface between the RGIS store mapping output to all commonly used analytical software applications.

PRINCETON, New Jersey and MILAN, Italy, April 25 /PRNewswire/ --

- 85% of patients achieve undetectable HCV RNA levels following 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus Copegus(R) -

- Safety and tolerability comparable to placebo administered with Pegasys plus Copegus -

- EASL presentation available on Pharmasset website -

- Conference call scheduled for Friday, April 25, 2008 at 1:00 PM ET (US) and 7:00 PM CEST (Milan) -

INGELHEIM, Germany, April 25 /PRNewswire/ --

- For non-US Healthcare Media

- Abstract # 163O. von Pawel. Proffered Papers 6 - Advanced NSCLC

- Latest Phase II Data for Boehringer Ingelheim's New Cancer Drug in Development Presented

BERLIN, April 25 /PRNewswire/ -- Processes and products based on biomass and industrial biotechnology offer significant business potential for the chemical industry in a wide range of applications such as bioplastics. A panel on developments in the field of industrial biotechnology in Germany will be held at the World Congress on Industrial Biotechnology and Bioprocessing (April 27-30, 2008) in Chicago, Illinois. The panel runs from 10:45am to 12:15pm on April 28th at the Hilton Chicago, 720 South Michigan Ave.

SUMY, Ukraine, April 25 /PRNewswire/ -- JSC Sumy Frunze NPO (KSE:SMASH), Ukraine's premier machine-building corporation in the petroleum sector, today announced substantially higher 1Q sales, along with ambitious plans to double gross revenue within two years. By 2009, Sumy Frunze NPO aims to reach a US$600 million sales target, double sales for 2007, Victor Choban, general manager, said.

Sumy Frunze NPO production capacity having been expanded, the company's newly declared priority is attracting more customers to fully utilize this capacity.

In 1Q 2008, Sumy Frunze NPO boosted sales four-fold, to US$168.15 million, compared with US$38.13 million in 1Q 2007.

REDMOND, Washington, April 25 /PRNewswire/ --

- FAST CEO John Markus Lervik to lead Microsoft's enterprise search business.

Microsoft Corp today announced that it has completed settlement of its tender offer for Fast Search & Transfer ASA, a leading provider of enterprise search solutions. Microsoft's plans to acquire FAST were originally announced 8 Jan 2008. FAST will operate as a Microsoft subsidiary, with a dedicated enterprise search research and development centre in Oslo, Norway, and offices throughout the world.

(Logo: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO)

We go back a long way with herpesviruses. Our evolutionary line has been living with these genomic parasites for more than 100 million years, and today herpesviruses infect nearly all humans, as well as all other mammals, birds and reptiles that scientists have checked. We aren't born with these viruses, but most of us acquire multiple infections of various types of herpesviruses during childhood.

Unlike our relationship with many other, more notorious viruses, we've learned to peacefully coexist with herpesviruses for the most part. They set up shop in our cells, they use our molecular machinery to replicate themselves, and they take advantage of the influx of energy we provide from our diet. Sometimes the relationship goes sour, with the unfortunate results ranging from chickenpox to mononucleosis, genital herpes, and Burkitt's lymphoma, but by and large, most humans, and mammals in general, are never seriously harmed by these house guests. But do we get anything out of this relationship? Remarkably, recent research suggests that this 100 million-year coexistence may have been good for us too, helping our immune system to ward off even more serious pathogens.


Photo Credit: US Centers for Disease Control, courtesy of the Wikipedia Commons

LONDON, April 25 /PRNewswire/ -- Unite, the UK's biggest union, today condemned the announcement by electrical goods firm JVC that it will close its East Kilbride electronic plant with the loss of 300 local jobs.

Workers were told the news at a canteen meeting called by management this morning, Friday, 25th April 2008. The plant, which makes LCD television sets, will shift production to Eastern Europe in July.

Unite Regional Officer, Jimmy Farrelly, said: "Our members are absolutely stunned by this news. We have been involved in pay negotiations with the company recently and there was no mention whatsoever that the future of the plant was in doubt.

LONDON, April 25 /PRNewswire/ -- They may be called bed bugs but they do not just live in beds. They can make their home anywhere that their human food source is stationary for any length of time and in virtually any surface or material.

Bed bugs are now making a big comeback and after receiving over 258,000 hits in one day on their website, Bed Bugs Ltd., the UK's leading specialist bed bug control company, has launched a new service Off Site Decon(TM).

BASINGSTOKE, England and PHILADELPHIA, April 25 /PRNewswire/ --

- All Figures are in US$

Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the three months to March 31, 2008.

Q1 2008 Financial Highlights - Product sales up 37% to $632m - New product sales(1) $216m, 34% of product sales (2007: 13%) - Total revenues up 33% to $702m - US GAAP Operating income up 15% to $163m - Non GAAP Operating income up 23% to $192m - US GAAP Earnings per ADS up 7% to $0.68 - Non GAAP Earnings per ADS up 5% to $0.74

(1) New product sales include DAYTRANA, DYNEPO, ELAPRASE, FOSRENOL, LIALDA/MEZAVANT and VYVANSE

Matthew Emmens, Chief Executive Officer, commented: